|
1 2 3 4 5 6 7 8 9
KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE
February 15, 2008
KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
November 20, 2007
KV Pharmaceutical Announces FDA Approval for Morphine ER 100 mg and 200 mg Tablets
October 25, 2007
KV Pharmaceutical Announces Launch of Two Strengths of Generic Versions of Toprol-XL®
July 26, 2007
KV Pharmaceutical Company Reports Preliminary Unaudited Fiscal 2007 Revenues
May 31, 2007
KV Pharmaceutical Company Announces Approval For Two Strengths of Generic Versions of Toprol-XL®
May 18, 2007
Jury Finds in Favor of ETHEX/KV on all Claims Against KV Pharmaceutical and ETHEX Subsidiary
March 6, 2007
KV Pharmaceutical Reports Preliminary Record Revenues for Fiscal 2007 Third Quarter and Nine-Months
February 7, 2007
KV Pharmaceutical Company Receives ANDA Approval From U.S. FDA For Six Strengths of Diltiazem HCl ER Capsules
September 12, 2006
KV Pharmaceutical Company Reports Fiscal 2007 First Quarter Results
August 8, 2006
|
|
The Press Releases shown in this section of the Web
site are presented for archival purposes only. The Press Releases are presented as they were
originally released. The Company makes no claim that the information contained in these materials
is currently accurate or is presented in a manner that would be appropriate for dissemination as
a press release at the present time. See
also KV
Pharmaceutical Company Web Site Terms of Use and Legal Restrictions and Product
Disclaimer.
|
